BREAKTHROUGH TREATMENT FOR THE UNDERLYING CAUSE OF CYSTIC FIBROSIS (CF)
ORKAMBI® (lumacaftor/ivacaftor) targets the complex protein defects of the F508del-CFTR protein1
Lumacaftor and ivacaftor work directly on the CFTR protein to increase chloride ion transport. In vitro responses do not necessarily correspond to in vivo pharmacodynamic response or clinical benefit.1See How ORKAMBI Works
MANAGING THERAPY IN YOUR PATIENTS TAKING ORKAMBI
Most common plans by state
Select your patient’s state, then download the PDF to view contact information for some of the most common insurers and Medicaid (current as of 02/2016).
- A member of your team or the patient can contact his/her payer to verify coverage and out-of-pocket expenses
- Depending on the patient’s insurance plan, benefits may be administered either through the payer or a Pharmacy Benefits Manager (PBM)
- ORKAMBI [prescribing information]. Boston, MA: Vertex Pharmaceuticals Incorporated; May 2016.